Abend Alon, Shkedi Omer, Fertouk Michal, Caspi Lilac H, Kehat Izhak
The Rappaport Institute and the Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
Department of Cardiac Surgery, Rambam Medical Center, Haifa, Israel.
EMBO Rep. 2017 Jul;18(7):1166-1185. doi: 10.15252/embr.201643686. Epub 2017 Jun 6.
A pathologic osteochondrogenic differentiation of vascular smooth muscle cells (VSMCs) promotes arterial calcifications, a process associated with significant morbidity and mortality. The molecular pathways promoting this pathology are not completely understood. We studied VSMCs, mouse aortic rings, and human aortic valves and showed here that histone deacetylase 4 (HDAC4) is upregulated early in the calcification process. Gain- and loss-of-function assays demonstrate that HDAC4 is a positive regulator driving this pathology. HDAC4 can shuttle between the nucleus and cytoplasm, but in VSMCs, the cytoplasmic rather than the nuclear activity of HDAC4 promotes calcification, and a nuclear-localized mutant of HDAC4 fails to promote calcification. The cytoplasmic location and function of HDAC4 is controlled by the activity of salt-inducible kinase (SIK). Pharmacologic inhibition of SIK sends HDAC4 to the nucleus and inhibits the calcification process in VSMCs, aortic rings, and In the cytoplasm, HDAC4 binds and its activity depends on the adaptor protein ENIGMA (Pdlim7) to promote vascular calcification. These results establish a cytoplasmic role for HDAC4 and identify HDAC4, SIK, and ENIGMA as mediators of vascular calcification.
血管平滑肌细胞(VSMC)的病理性骨软骨分化会促进动脉钙化,这一过程与显著的发病率和死亡率相关。促进这种病理过程的分子途径尚未完全明确。我们对VSMC、小鼠主动脉环和人类主动脉瓣进行了研究,结果表明组蛋白去乙酰化酶4(HDAC4)在钙化过程早期上调。功能获得和功能丧失实验表明,HDAC4是驱动这种病理过程的正向调节因子。HDAC4可在细胞核和细胞质之间穿梭,但在VSMC中,HDAC4的细胞质而非细胞核活性促进钙化,并且HDAC4的核定位突变体无法促进钙化。HDAC4的细胞质定位和功能受盐诱导激酶(SIK)活性的控制。对SIK的药理抑制会使HDAC4进入细胞核,并抑制VSMC、主动脉环中的钙化过程。在细胞质中,HDAC4结合,其活性取决于衔接蛋白ENIGMA(Pdlim7)以促进血管钙化。这些结果确定了HDAC4在细胞质中的作用,并将HDAC4、SIK和ENIGMA鉴定为血管钙化的介质。